['low back pain']
['sta363', 'placebo']

        Inclusion Criteria:

          -  Signed informed consent prior to any study-related procedures

          -  Chronic discogenic low back pain present for more than 6 months prior to the screening
             visit

          -  20 to 60 years of age at the screening visit

          -  Insufficient response to at least 6 months of non-operative treatment (analgesics
             and/or antiinflammatory medication, physiotherapy etc.)

          -  A single lumbar disc appropriate for treatment at L3/4 to L5/S1, based on clinical
             evaluation by the investigator

          -  Pfirrmann grade II-III

          -  Ability to understand the written and verbal information about the study

        Exclusion Criteria:

          -  Treatment with any investigational product within 3 months prior to the screening
             visit

          -  More than one painful intervertebral disc

          -  A painful intervertebral disc above L3/4 level

          -  Current infection or prior history of spinal infection (e.g., discitis, septic
             arthritis, epidural abscess) or an active systemic infection

          -  Previous lumbar spine surgery

          -  Previous disc invasive treatment procedures at the affected level(s) (e.g.,
             intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation)

          -  Pfirrmann grade I, IV and V

          -  Evidence of prior lumbar vertebral body fracture or trauma

          -  Need for spinal decompression assessed by the investigator

          -  Presence of disc extrusion or sequestration

          -  Patients previously included in the study

          -  Patients suffering from psychosomatic pain in the opinion of the investigator

          -  Referred leg pain of compressive origin

          -  Known alcohol and/or drug abuse

          -  Severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or
             concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the
             investigator, may put the patient at risk when participating in the study, or affect
             the patient's ability to take part in the study

          -  Clinically significant abnormalities in clinical chemistry or haematology parameters
             as assessed by the investigator

          -  Pregnant or lactating females or intention to become pregnant within the study period

          -  Known allergy to any of the components of the drug product or placebo

          -  Known opioid allergy or intolerance

          -  Patients requiring treatment with warfarin or other anticoagulant therapy

          -  Unwillingness to refrain from treatment with non-steroidal anti-inflammatory drugs
             (NSAIDs) within 5 days before the planned study treatment

          -  Body weight less than 50 kg
      